Eluminate-5
Research type
Research Study
Full title
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)
IRAS ID
1013699
Contact name
Diana Ionescu
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
This is a trial to learn how safe the combination of elecoglipron with dapagliflozin is and how well it works in adults living with type 2 diabetes mellitus compared to elecoglipron alone or dapagliflozin alone.
Medicines called GLP-1 receptor agonists (GLP-1 RA) have been used for about 20 years to treat T2DM and most of the GLP-RAs are taken as injections. GLP-1 RAs lower blood sugar and can help you feel less hungry and fuller for longer, which may also help with weight loss. Elecoglipron is a GLP-1 RA that is being developed as a tablet participant can take by mouth. The main purpose of this study is to find out if elecoglipron, either alone or in combination with another medicine called dapagliflozin, can help people with T2DM improve their overall health.
This study is "double-blind," which means neither participant nor study doctor will know which treatment participant get while the study is ongoing. This helps make sure the results are fair and unbiased. However, participant will be randomly assigned to one of the treatment groups. This means that the treatment group participant is placed in will be decided by chance.
Before starting the study treatment, participant will have a series of assessment and tests during the screening period. These tests check if participant is eligible to take part in the study. The titration period is the first part of the treatment period. Participant will start the study medication at a low dose, and the dose will be slowly increased step by step over several weeks (i.e. titrated), so you can safely reach your target dose.
At each study visit, doctor will check on participant to make sure the medication is working and that you are not having any significant side effects.REC name
London - Surrey Borders Research Ethics Committee
REC reference
26/LO/0277
Date of REC Opinion
17 Jun 2026
REC opinion
Further Information Favourable Opinion